Nuvectis Pharma Receives Marketing Approval for Ciprocopan in China to Treat PNH

Key Facts

In a move reflecting the strategic expansion of biotech firms into Asian markets, Nuvectis Pharma has reached a significant regulatory milestone. The company's drug ciprocopan (NXP100) received marketing approval from China's National Medical Products Administration (NMPA). This oral complement Factor B inhibitor is specifically approved for treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously been treated with complement inhibitors.

The approval marks a major step for the company's clinical-stage pipeline, offering a once-daily oral therapy for complement-related conditions. Per market data, NVCT stock closed at $19.29 on July 22, 2026, within a daily range of $19.01 to $19.75. This regulatory success coincides with a period of monetary stability in China, where the Prime Rate was maintained at 3% as of July 20, 2026.

Traders should watch NVCT price levels, which stood at $19.29 (close July 22, 2026), as the company transitions toward commercialization in China. While the upcoming economic calendar does not list immediate pharmaceutical catalysts, the broader stability in Chinese lending rates may provide a supportive backdrop for healthcare sector investments.